Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7475 pages
Showing 1701 - 1750Long-Term Outcomes After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab for Triple-Negative Breast Cancer
In an analysis from the phase II CALGB 40603/Alliance trial reported in the Journal of Clinical Oncology, Shepherd et al found that the addition of carboplatin or bevacizumab to neoadjuvant chemotherapy was not associated with improved long-term outcomes in patients with stage II or III...
Pembrolizumab in Previously Treated Patients With MSI-H/dMMR Endometrial Cancer
As reported in the Journal of Clinical Oncology by David M. O’Malley, MD, and colleagues, pembrolizumab showed durable activity in a cohort of patients with microsatellite instability–high or mismatch repair–deficient (MSI-H/dMMR) advanced endometrial cancer enrolled in the multicohort KEYNOTE-158...
Pretreatment Cardiovascular Disease and Events During Follow-up in Patients Receiving Curative-Intent Chemoradiation for Esophageal Cancer
In a Danish single-institution study reported in JACC: CardioOncology, Søndergaard et al found a high rate of undetected or inadequately treated preexisting cardiovascular disease prior to the receipt of chemoradiation and a high rate of cardiovascular events during follow-up in patients undergoing ...
Erdafitinib for Patients With Advanced Urothelial Carcinoma and FGFR Alterations
As reported in The Lancet Oncology by Arlene O. Siefker-Radtke, MD, and colleagues, the final analysis of the phase II BLC2001 trial has shown maintained activity of the pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor erdafitinib in patients with locally advanced unresectable ...
Long-Term Swallowing Quality-of-Life Results With Radiotherapy vs Transoral Robotic Surgery for Oropharyngeal Cancer
In a long-term longitudinal analysis of the phase II ORATOR trial reported in the Journal of Clinical Oncology, Anthony Nichols, MD, and colleagues found that a statistically significant improvement in swallowing quality of life persisted through 3 years after treatment with radiotherapy vs...
Does Early Locoregional Therapy for the Primary Site Improve Survival in Newly Diagnosed Metastatic Breast Cancer?
In the phase III ECOG-ACRIN E2108 trial reported in the Journal of Clinical Oncology, Seema A. Khan, MD, MPH, and colleagues found no difference in overall survival with early locoregional therapy vs continued systemic therapy among women with newly diagnosed stage IV breast cancer and an intact...
Impact of a Healthy Lifestyle on Risk of Developing Cancer, Cardiovascular Disease, or Type 2 Diabetes
In a study reported in JACC: CardioOncology, Cao et al found that fulfillment of more components of a healthy lifestyle was associated with a reduced risk of developing cancer in a baseline cancer-free cohort, and a reduced risk of developing cardiovascular disease and type 2 diabetes in both the...
Addition of Diet and Lifestyle Factors to Recurrence and Mortality Prediction Models for Patients With Stage III Colon Cancer
In a study reported in the Journal of Clinical Oncology, Cheng et al found that the addition of patient-reported diet and lifestyle factors to prediction models based on clinical and pathologic characteristics improved predictions of disease recurrence and mortality among patients with stage III...
Selecting Patients With Barrett's Esophagus for Endoscopic Surveillance: Role of Nonendoscopic Device Biomarkers
In a study reported in The Lancet Oncology, Pilonis et al found that nonendoscopic cell collection device (marked as the Cytosponge)–detected atypia and p53 overexpression could be used in combination with clinical risk factors to triage patients with Barrett’s esophagus for endoscopic...
Personalized Lung Cancer Risk Assessment Using a Blood-Based Biomarker Panel
In a study reported in the Journal of Clinical Oncology, Fahrmann et al found that a four-component blood-based biomarker panel showed predictive ability for the development of lung cancer. Prediction was improved when the panel was used in conjunction with the Prostate, Lung, Colorectal and...
Inotuzumab Ozogamicin for Pediatric Patients With Relapsed or Refractory B-Cell ALL
In a phase II trial (Children’s Oncology Group AALL1621) reported in the Journal of Clinical Oncology, O’Brien et al found that inotuzumab ozogamicin produced a high response rate in children and adolescents with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Study Details In the ...
Addition of Nivolumab to Oxaliplatin-Based Chemotherapy for HER2-Negative, Unresectable, Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer
In an Asian phase II/III trial (ATTRACTION-4) reported in The Lancet Oncology, Yoon-Koo Kang, MD, and colleagues found that the addition of nivolumab to oxaliplatin-based chemotherapy improved progression-free survival—but not overall survival—as first-line treatment of HER2-negative, unresectable, ...
Interferon-Alfa vs Hydroxyurea in Previously Untreated Patients With Polycythemia Vera and Essential Thrombocythemia
In a phase III trial (MPD-RC 112) reported in the journal Blood, John Mascarenhas, MD, and colleagues found no difference in 12-month complete response rates between treatment with pegylated interferon-alfa vs hydroxyurea in previously untreated patients with high-risk polycythemia vera or...
Depression Screening and Behavioral Health Referrals for Patients With Newly Diagnosed Breast Cancer in the Community Oncology Setting
In a study reported in JAMA, Hahn et al found that a depression screening and intervention program resulted in a higher rate of referral to behavioral health services vs education alone among patients with newly diagnosed breast cancer at community oncology centers located in Southern California....
First-Line Nivolumab/Cabozantinib vs Sunitinib for Advanced Renal Cell Carcinoma: Patient-Reported Outcomes
In an analysis from the phase III CheckMate 9ER trial reported in The Lancet Oncology, David Cella, PhD, FASCO, and colleagues found that nivolumab/cabozantinib was associated with maintained or improved patient-reported outcomes vs sunitinib in the first-line treatment of advanced renal cell...
Addition of Capecitabine to Taxane/Anthracycline Adjuvant Chemotherapy for Early Breast Cancer: 15-Year Overall Survival Results of the FinXX Trial
As reported in the Journal of Clinical Oncology by Heikki Joensuu, MD, and colleagues, 15-year overall survival results from the Finland Capecitabine Trial (FinXX) showed that the addition of capecitabine to taxane/anthracycline adjuvant chemotherapy was associated with improved overall survival...
Association of Genetic Alterations With Disease Characteristics and Response to Treatment in Pediatric Differentiated Thyroid Cancer
In a study reported in the Journal of Clinical Oncology, Franco et al found that RET and NTRK fusions were common somatic genetic alterations in pediatric patients with differentiated thyroid cancer and were associated with an increased risk of metastasis and poorer treatment outcome. Study ...
Composition of Academic Radiation Oncology Workforces in National Cancer Institute–Designated Comprehensive Cancer Centers
In a study reported in JCO Oncology Practice, McClelland et al found that among academic radiation oncologists at National Cancer Institute–designated Comprehensive Cancer Centers (CCCs), less than 5% were from underrepresented minority groups, senior faculty included more men than women, and women ...
Antibiotics After Endoprosthetic Reconstruction for Lower-Extremity Bone Tumors: Comparison of Two Intravenous Regimens
In a study reported in JAMA Oncology, researchers in the Prophylactic Antibiotic Regimens in Tumor Surgery Investigators group found that 5 days vs 1 day of postoperative intravenous antibiotic prophylaxis did not reduce the incidence of surgical site infection and was associated with more...
Paclitaxel/Carboplatin vs Paclitaxel/Ifosfamide in Chemotherapy-Naive Patients With Uterine Carcinosarcoma
As reported in the Journal of Clinical Oncology by Powell et al, the phase III NRG Oncology GOG-0261 trial has shown that paclitaxel/carboplatin is noninferior to paclitaxel/ifosfamide in terms of overall survival among chemotherapy-naive patients with uterine carcinosarcoma. Study Details The...
Global Burden of Cancer From 2010 to 2019
In an analysis reported in JAMA Oncology, researchers in the Global Burden of Disease 2019 Cancer Collaboration found a global increase in new cases of cancer, cancer deaths, and cancer-related disability-adjusted life-years (DALYs) between 2010 and 2019, with aspects of cancer burden differing...
Association of Autoantibodies to Gastric Mucosa and Risk of Gastric Cancer
In a case-control study reported in JAMA Oncology, Minkyo Song, MD, PhD, and colleagues found that seropositivity for gastric antiparietal cell antibodies (APCAs) was associated with an increased risk of gastric cancer among younger Finnish women who were seronegative for antibodies to Helicobacter ...
Effect of Daily Sitting Time and Weekly Physical Activity on Cancer Survivorship
In a study reported in JAMA Oncology, Cao et al found that the combination of increased daily sitting time and low weekly leisure-time physical activity was associated with poorer overall and cancer-specific survival among U.S. cancer survivors. Study Details The study involved data from a...
Atezolizumab/Bevacizumab vs Sunitinib in Previously Untreated Patients With Metastatic RCC: Final Overall Survival Analysis of IMmotion151
As reported in JAMA Oncology by Robert J. Motzer, MD, and colleagues, the final overall survival analysis of the phase III IMmotion151 trial has shown no significant difference for atezolizumab plus bevacizumab vs sunitinib in previously untreated patients with metastatic renal cell carcinoma...
Is There an Association Between Maternal Hormonal Contraception Use and Risk of CNS Tumors in Children?
In a Danish nationwide cohort study reported in JAMA, Hargreave et al found no association between maternal hormonal contraception use and risk of central nervous system (CNS) tumors in children. As stated by the investigators, “The incidence of CNS tumors in children appears to be increasing, yet...
Palliative Care Use Among Commercially Insured U.S. Patients With Metastatic Cancer: 2001–2016
In a study reported in JCO Oncology Practice, Ferrario et al found that while use of palliative care among commercially insured patients aged 25 to 64 years in the United States with metastatic cancer has increased since 2001, use remained at 40% among patients with very poor–prognosis cancers in...
Addition of Abiraterone Acetate and Prednisolone With or Without Enzalutamide to ADT in High-Risk Nonmetastatic Prostate Cancer
In a meta-analysis of two STAMPEDE platform phase III trials reported in The Lancet, Gerhardt Attard, PhD, and colleagues found that the addition of abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy (ADT) was associated with improved metastasis-free...
Immunogenicity of COVID-19 BNT162b2 mRNA Vaccine Booster in Patients With Cancer Receiving Active Treatment
In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving active cancer treatment. Antibody levels prior to and...
Effect of Recent Prior Radiotherapy on Adverse Events in Patients Receiving Immune Checkpoint Inhibitors
In a pooled analysis of individual patient data from trials in the U.S. Food and Drug Administration database reported in JAMA Oncology, Anscher et al found that patients with cancer receiving radiotherapy within 90 days prior to the start of immune checkpoint inhibitor treatment were not at...
Response-Adapted Omission of Radiotherapy and Comparison of Consolidation Therapy in Pediatric Classical Hodgkin Lymphoma
In analyses from the European EuroNet-PHL-C1 study reported in The Lancet Oncology, Mauz-Körholz et al found that radiotherapy could be omitted in pediatric patients with intermediate- or advanced-stage classical Hodgkin lymphoma who had adequate response to induction with OEPA (vincristine,...
Addition of Anti–LAG-3 Antibody Relatlimab to Nivolumab in Previously Untreated Patients With Advanced Melanoma
In the phase II/III RELATIVITY-047 trial reported in The New England Journal of Medicine, Hussein A. Tawbi, MD, PhD, and colleagues found that the addition of relatlimab, a lymphocyte-activation gene 3 (LAG-3)-blocking antibody, to nivolumab, a PD-1 inhibitor, significantly prolonged...
Trends in Population-Level Stage Shift and Mortality Among U.S. Patients With NSCLC: 2006–2016
In a retrospective cohort study reported in JAMA Network Open, Raja Flores, MD, and colleagues found that a population-level shift to earlier-stage diagnosis has been accompanied by a reduction in population-level mortality during recent years in U.S. patients with non–small cell lung cancer...
Health-Related Quality of Life With Enzalutamide vs Standard of Care for Metastatic Hormone-Sensitive Prostate Cancer: ENZAMET Trial
As reported in the Journal of Clinical Oncology by Stockler et al, enzalutamide was associated with worsening in several quality-of-life domains—but not in overall health and quality of life—vs standard of care in the phase III ENZAMET trial evaluating the efficacy of the agent for patients with...
Does Armodafinil Improve Cancer-Related Fatigue in Patients With High-Grade Glioma?
In a phase III trial reported in JAMA Oncology, Porter et al found that armodafinil, a psychostimulant, did not improve cancer-related fatigue vs placebo in adult patients with high-grade glioma. As stated by the investigators, “Nearly 96% of patients with high-grade glioma report...
Bispecific Antibody Mosunetuzumab in Relapsed or Refractory B-Cell Lymphomas
In a phase I study reported in the Journal of Clinical Oncology, L. Elizabeth Budde, MD, PhD, and colleagues found that the CD20-CD3 bispecific antibody mosunetuzumab produced durable responses in patients with relapsed or refractory aggressive and indolent B-cell non-Hodgkin lymphomas....
Interim Radiographic Assessment for Adaptive Dosing of Combination Immunotherapy in Advanced Melanoma
In the phase II ADAPT-IT trial reported in the Journal of Clinical Oncology, Michael A. Postow, MD, and colleagues showed that findings on interim computed tomography (CT) allowed patients to avoid the third and fourth doses of combination nivolumab/ipilimumab for the treatment of advanced...
Apatinib for Advanced Radioactive Iodine–Refractory Differentiated Thyroid Cancer
In an interim analysis of the Chinese phase III REALITY trial reported in JAMA Oncology, Lin et al found that apatinib, a highly selective VEGFR2 inhibitor, significantly prolonged progression-free survival vs placebo in patients with progressive, locally advanced or metastatic, radioactive...
Comparison of Efficiency of USPSTF vs PLCO Criteria in Determining Eligibility for Lung Cancer Screening
In an interim analysis of a prospective cohort study reported in The Lancet Oncology, Tammemägi et al found that the Prostate Lung Colorectal and Ovarian Cancer Screening Trial 2012 risk prediction model (PLCOm2012) may be more efficient than U.S. Preventive Services Task Force 2013 (USPSTF2013)...
Pretreatment Disease Burden and Outcomes With Commercial Tisagenlecleucel in Pediatric/Young Adult B-Cell ALL
In an analysis from the Pediatric Real-World Chimeric Antigen Receptor Consortium reported in the Journal of Clinical Oncology, Schultz et al found that pretreatment high disease burden was associated with poorer outcomes in pediatric and young adult patients who received commercial...
Association of HLA-A*03 With Outcomes of Immune Checkpoint Inhibition for Advanced Cancers
In a study reported in The Lancet Oncology, Naranbhai et al found that the presence of HLA-A*03 was associated with poorer outcomes in patients receiving immune checkpoint inhibitors for advanced cancers. As stated by the investigators, “Predictive biomarkers could allow more precise use of immune...
Association of Response Rate and Event-Free Survival With Overall Survival in Newly Diagnosed AML: FDA Analysis
In a trial-level analysis of randomized studies submitted to the U.S. Food and Drug Administration (FDA) reported in the Journal of Clinical Oncology, Norsworthy et al found that complete remission rate was moderately correlated, and event-free survival was strongly correlated, with overall...
Long-Term Outcomes According to Residual Cancer Burden After Neoadjuvant Chemotherapy for Breast Cancer
In an analysis reported in The Lancet Oncology, Yau et al found that increasing residual cancer burden (RCB) after neoadjuvant chemotherapy was associated with poorer event-free survival across breast cancer subtypes. Study Details The study included patient-level data on RCB and other clinical and ...
MRD Response–Adapted Therapy in Patients Receiving Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Plus AHCT for Newly Diagnosed Multiple Myeloma
In the phase II MASTER trial reported in the Journal of Clinical Oncology, Luciano J. Costa, MD, PhD, and colleagues found that daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) induction; autologous hematopoietic cell transplantation (AHCT); and measurable residual disease (MRD) ...
European Genome-Wide Association Study of Genetic Variants in Alcohol-Related Hepatocellular Carcinoma
In a case-control genome-wide association study among persons of European ancestry reported in The Lancet Oncology, Trépo et al identified common genetic variants associated with the risk of alcohol-related hepatocellular carcinoma (HCC). Study Details The study involved a discovery cohort of 2,107 ...
Balstilimab Plus Zalifrelimab for the Second-Line Treatment of Advanced Cervical Cancer
In a phase II trial reported in the Journal of Clinical Oncology, David M. O’Malley, MD, and colleagues found that the PD-1 inhibitor balstilimab and the CTLA-4 inhibitor zalifrelimab—both investigational agents—produced durable responses as second-line treatment for patients with recurrent or...
Polatuzumab Vedotin-piiq Plus R-CHP vs R-CHOP for Previously Untreated Patients With DLBCL
In the phase III POLARIX trial reported in The New England Journal of Medicine, Tilly et al found that polatuzumab vedotin-piiq plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisone) significantly improved progression-free survival vs R-CHOP (rituximab, cyclophosphamide, doxorubicin, ...
Association of MRD Response and Prognosis in Patients With AML Treated With Venetoclax and Azacitidine
�In an analysis from the phase III VIALE-A study reported in the Journal of Clinical Oncology, Keith W. Pratz, MD, and colleagues found that among treatment-naive patients with acute myeloid leukemia (AML) who experienced complete remission after receiving treatment with venetoclax/azacitidine,...
Hepatic Arterial Infusion Chemotherapy vs Sorafenib for Advanced Hepatocellular Carcinoma
In a Chinese phase III trial (FOHAIC-1) reported in the Journal of Clinical Oncology, Lyu et al found that hepatic arterial infusion chemotherapy with FOLFOX (fluorouracil, leucovorin, and oxaliplatin; HAIC-FO) significantly prolonged overall survival vs sorafenib in patients with advanced...
Second-Line Tisagenlecleucel vs Standard of Care in Aggressive B-Cell Lymphoma
As reported in The New England Journal of Medicine by Bishop et al, the phase III BELINDA trial showed no improvement in event-free survival with second-line tisagenlecleucel vs standard of care including salvage chemotherapy and autologous hematopoietic stem cell transplantation (HSCT) in patients ...
Personalized Therapy vs Physician’s Choice of Treatment for Patients With Residual Triple-Negative Breast Cancer After Neoadjuvant Chemotherapy
In a phase II trial reported in the Journal of Clinical Oncology, Schneider et al found that genomically directed therapy did not improve 2-year disease-free survival vs treatment of physician’s choice in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy. Study ...
